Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 13/20 | 0.83 |
| ▸ | PYGL | P06737 | 13/20 | 0.83 |
| ▸ | ACLY | P53396 | 2/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432816 | 0.91 | PYGL (1.00) | PYGMPYGL | |
| SCHEMBL7125502 | 0.91 | PYGM (0.79) | PYGMPYGLHPSESERPINE1 | |
| SCHEMBL6431208 | 0.89 | PYGL (0.80) | PYGMPYGLHPSE | |
| SCHEMBL27716773 | 0.86 | PYGM (0.63) | PYGMPYGLACLYSERPINE1 | |
| SCHEMBL7119403 | 0.86 | PYGM (0.76) | PYGMPYGLHPSE | |
| SCHEMBL7119640 | 0.86 | PYGL (0.69) | PYGMPYGLHPSE | |
| SCHEMBL7116980 | 0.86 | PYGM (0.72) | PYGMPYGLHPSE | |
| SCHEMBL7123098 | 0.85 | PYGL (0.83) | PYGMPYGLHPSE | |
| SCHEMBL7117323 | 0.85 | PYGM (0.74) | PYGMPYGL | |
| SCHEMBL7128880 | 0.85 | PYGM (0.83) | PYGMPYGLHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | PYGM 3/4885PYGL 1/4885ACLY 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.